Achieve Life director receives options and RSUs

Achieve Life Sciences director Stewart Richard Alistair received equity awards on July 27, 2026: stock options for 25,000 shares at an exercise price of $6.18 per share and 16,700 RSUs, each RSU settling into one share.

Rhea-AI Filing Summary

Achieve Life Sciences director Stewart Richard Alistair received equity awards on July 27, 2026: stock options for 25,000 shares at an exercise price of $6.18 per share and 16,700 RSUs, each RSU settling into one share. Both awards vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual meeting of stockholders, subject to continued service, resulting in direct holdings of 25,000 options and 16,700 RSUs. The options expire on July 27, 2036.

Insider Trade Summary

Grant/Award: 41,700 shares

Grant/Award 2 txns

Insider Stewart Richard Alistair

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00
Grant/Award	Restricted Stock Unit (RSU) F2, F3	16,700	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct); Restricted Stock Unit (RSU) — 16,700 contracts (Direct)

Footnotes (3)

1. F1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
3. F3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

Key Figures

Stock options granted: 25,000 shares Option exercise price: $6.18 per share Option expiration date: July 27, 2036 +2 more

5 metrics

Stock options granted 25,000 shares Stock option grant to director on 2026-07-27

Option exercise price $6.18 per share Exercise price for 25,000-share option award

Option expiration date July 27, 2036 Expiration of director stock option grant

RSUs granted 16,700 units Restricted Stock Units granted on 2026-07-27

Vesting schedule Earlier of July 27, 2027 or before 2027 annual meeting Vesting terms for both options and RSUs, subject to service

Key Terms

Stock Option (right to buy), Restricted Stock Unit (RSU), vest 100% on the earlier of

3 terms

Stock Option (right to buy) financial

"Security title listed as Stock Option (right to buy) for the grant."

Restricted Stock Unit (RSU) financial

"Security title recorded as Restricted Stock Unit (RSU) in the transaction data."

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

vest 100% on the earlier of financial

"Footnote states the awards "vest 100% on the earlier of July 27, 2027"."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Achieve Life Sciences (ACHV) grant to director Stewart Richard Alistair?

Achieve Life Sciences granted the director 25,000 stock options at an exercise price of $6.18 per share and 16,700 RSUs. Each RSU represents a contingent right to receive one share of common stock at settlement, according to the filing footnotes.

What is the exercise price and expiration date of the new ACHV stock options?

The stock options have an exercise price of $6.18 per share and expire on July 27, 2036. These options cover 25,000 shares of Achieve Life Sciences common stock and were granted to director Stewart Richard Alistair on July 27, 2026.

When do the ACHV director’s options and RSUs vest?

Both the options and RSUs vest 100% on the earlier of July 27, 2027 or immediately before ACHV’s 2027 annual meeting of stockholders. Vesting is conditioned on the director continuing to provide service to the company through the applicable vesting date.

How many ACHV shares could be issued from the RSUs reported in this Form 4?

The award includes 16,700 RSUs, each representing a contingent right to receive one share of ACHV common stock. If fully vested and settled in shares, the RSUs would therefore correspond to 16,700 shares of Achieve Life Sciences common stock.

Does this ACHV Form 4 reflect a market purchase or a compensatory grant?

The transactions are grant/award acquisitions, not market purchases. They consist of compensatory stock option and RSU awards granted to a director, both reported with transaction code “A” for grant, award, or other acquisition, at a stated exercise price only for the options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 05:20 PM Accepted by SEC EDGAR 07/29/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stewart Richard Alistair

(Last) (First) (Middle)

22722 29TH DR SE

SUITE 100

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.18	07/27/2026		A		25,000		(1)	07/27/2036	Common Stock	25,000	$0	25,000	D
Restricted Stock Unit (RSU)	(2)	07/27/2026		A		16,700		(3)	07/27/2036	Common Stock	16,700	$0	16,700	D

Explanation of Responses:

1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.

3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

	Sandra Thomson as attorney-in-fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)